Gilead Sciences Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Gilead Sciences Inc (GILD). It shows which part of the business is growing — and which one is holding it back.
Revenue by region
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| United States | $18.22B 73.8% | $19.27B 70.6% · +5.8% | $18.88B 69.2% · -2.0% | $19.44B 71.7% · +2.9% | $20.59B 71.6% · +5.9% | $20.88B 70.9% · +1.4% |
| Europe | $4.14B 16.7% | $4.87B 17.9% · +17.9% | $4.47B 16.4% · -8.3% | $4.31B 15.9% · -3.6% | $4.63B 16.1% · +7.5% | $5.06B 17.2% · +9.3% |
| Rest of World | – | – | $3.93B 14.4% | $3.37B 12.4% · -14.3% | $3.53B 12.3% · +4.8% | $3.50B 11.9% · -0.7% |
| Other International | $2.34B 9.5% | $3.16B 11.6% · +35.4% | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.